Global Dalfampridine Market Size, Share, and Trends Analysis Report, By Application (Multiple Sclerosis and Neurological Disorders) and By Distribution Channel (Hospital Pharmacies and Retail Drug Stores), Forecast (2022-2028)

The global dalfampridine market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). Dalfampridine is a drug used for the treatment of several symptoms caused by multiple sclerosis and other neurological disorders. The symptoms include electric shock sensation due to certain neck movements, lack of coordination between the limbs, numbness or weakness in limbs in the morning that typically occurs on one side of the body. The major factor attributing to the growth of the global dalfampridine market is the rising prevalence of multiple sclerosis across the globe. According to the report published by the National Library of Medicine (NIH) in December 2020, around 2.8 million people are estimated to have multiple sclerosis globally. The prevalence of multiple sclerosis is around 35.9 in every 1,00,000 population and is estimated to increase during the forecast period. Females are more likely to have multiple sclerosis than males. Thus, boosting the demand for dalfampridine for its treatment.

In addition, the application of dalfampridine is also increasing in the treatment of symptoms of other neurological disorders including headaches, stroke, epilepsy or seizures, amyotrophic lateral sclerosis (ALS), dementia, Alzheimer’s disease, and Parkinson’s disease. According to the World Health Organization (WHO), hundreds of million people are suffering from various neurological disorders globally. Mortality of around 6 million people occurs due to stroke every year. More than 50 million people are having epilepsy globally, and around 7.7 million new cases of dementia are registered every year. This rising prevalence of neurological disorders is increasing the demand for dalfampridine.

The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in December 2021, China extended its state insurance coverage by adding 74 new medicines to its medical insurance catalog. The newly added medicines are antibiotics, gynecological drugs, cancer drugs, and others. Dalfampridine with the brand name “Ampyra” which is used for the treatment of rare disease, multiple sclerosis is also included in this catalog.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape– Acorda Therapeutics, Inc., Perrigo, Biogen Inc., Aurobindo Pharma Ltd., and Sun Pharmaceuticals Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Dalfampridine  Market Report by Segment

By Application

• Multiple Sclerosis
• Neurological Disorders

By Distribution Channel

• Hospital Pharmacies
• Retail Drug Stores

Global Dalfampridine  Market Report by Region

North America

• The United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa